Patents by Inventor Young-Myeong Kim

Young-Myeong Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11702449
    Abstract: Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: July 18, 2023
    Assignee: AVIXGEN INC.
    Inventors: Young Myeong Kim, Yi Yong Baek, Won Jin Park, Jeong Hun Kim, Dong Hyun Jo
  • Publication number: 20210292363
    Abstract: Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.
    Type: Application
    Filed: May 17, 2021
    Publication date: September 23, 2021
    Applicant: AVIXGEN INC.
    Inventors: Young Myeong KIM, Yi Yong BAEK, Won Jin PARK, Jeong Hun KIM, Dong Hyun JO
  • Patent number: 11040999
    Abstract: Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: June 22, 2021
    Assignee: AVIXGEN INC.
    Inventors: Young Myeong Kim, Yi Yong Baek, Won Jin Park, Jeong Hun Kim, Dong Hyun Jo
  • Publication number: 20190315803
    Abstract: Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.
    Type: Application
    Filed: July 5, 2016
    Publication date: October 17, 2019
    Applicant: AVIXGEN INC.
    Inventors: Young Myeong KIM, Yi Yong BAEK, Won Jin PARK, Jeong Hun KIM, Dong Hyun JO
  • Patent number: 10086028
    Abstract: The present disclosure discloses a method for treating vascular inflammation, improving skin beauty and improving male sexual function of a subject by administering a ginseng berry extract to the subject.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: October 2, 2018
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Chan-Woong Park, Myeong Hoon Yeom, Nam Hoon Cho, Sang Jun Lee, Sang Min Lee, Jin Young Lee, Hee Yong Jeon, Young-Myeong Kim, Chun-Ki Kim, Young Deuk Choi
  • Patent number: 9969771
    Abstract: Provided are a tetrapeptide for inhibiting VEGF-induced angiogenesis and a use thereof, and particularly, provided is a peptide having the amino acid sequence of R-X1-X2-E (wherein X1 is leucine (L), isoleucine (I) or valine (V), and X2 is tyrosine (Y) or phenylalanine (F)) for inhibiting angiogenesis, or preventing, improving or treating cancer. This research was supported by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea, in 2011 and 2013 [NRF-2011-0028790 and 2013M3A9B6046563]. The tetrapeptide may effectively inhibit VEGF-induced angiogenesis or growth of cancer cells without a risk of side effects, and therefore may be expected to exhibit an excellent anticancer effect.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: May 15, 2018
    Assignee: AVIXGEN INC.
    Inventors: Young Myeong Kim, Yi Yong Baek, Dong Keon Lee, Jun-Sub Choi, Min Jung Kim, Hye Cheong Koo
  • Patent number: 9597365
    Abstract: The present disclosure discloses a method for treating vascular inflammation, improving skin beauty and improving male sexual function of a subject by administering a ginseng berry extract to the subject.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: March 21, 2017
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Chan-Woong Park, Myeong Hoon Yeom, Nam Hoon Cho, Sang Jun Lee, Sang Min Lee, Jin Young Lee, Hee Yong Jeon, Young-Myeong Kim, Chun-Ki Kim, Young Deuk Choi
  • Publication number: 20170037083
    Abstract: Provided are a tetrapeptide for inhibiting VEGF-induced angiogenesis and a use thereof, and particularly, provided is a peptide having the amino acid sequence of R-X1-X2-E (wherein X1 is leucine (L), isoleucine (I) or valine (V), and X2 is tyrosine (Y) or phenylalanine (F)) for inhibiting angiogenesis, or preventing, improving or treating cancer. This research was supported by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea, in 2011 and 2013 [NRF-2011-0028790 and 2013M3A9B6046563]. The tetrapeptide may effectively inhibit VEGF-induced angiogenesis or growth of cancer cells without a risk of side effects, and therefore may be expected to exhibit an excellent anticancer effect.
    Type: Application
    Filed: July 28, 2016
    Publication date: February 9, 2017
    Applicant: AVIXGEN INC.
    Inventors: Young Myeong KIM, Yi Yong BAEK, Dong Keon LEE
  • Patent number: 9314493
    Abstract: The present disclosure discloses a method for treating vascular inflammation, improving skin beauty and improving male sexual function of a subject by administering a ginseng berry extract to the subject.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: April 19, 2016
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Chan-Woong Park, Myeong Hoon Yeom, Nam Hoon Cho, Sang Jun Lee, Sang Min Lee, Jin Young Lee, HeeYong Jeon, Young-Myeong Kim, Chun-Ki Kim, Young Deuk Choi
  • Publication number: 20150183797
    Abstract: The present invention relates to a compound inhibiting Hsp90 and a pharmaceutical composition comprising the same as an active ingredient. The compounds represented by formula 1 and formula 2 of the present invention suppress the expression of Hsp90 so that they can inhibit the accumulation of HIF-1?, the Hsp90 client protein, and also efficiently inhibit the activation of VEGF. In addition, these compounds display low cytotoxicity, so that they can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.
    Type: Application
    Filed: January 2, 2015
    Publication date: July 2, 2015
    Applicant: SNU R&DB FOUNDATION
    Inventors: Young-Ger SUH, Dong-Jo CHANG, Hongchan AN, Kyu-Won KIM, Young-Myeong KIM, Ho-Young LEE
  • Publication number: 20140248226
    Abstract: The present disclosure discloses a method for treating vascular inflammation, improving skin beauty and improving male sexual function of a subject by administering a ginseng berry extract to the subject.
    Type: Application
    Filed: May 9, 2014
    Publication date: September 4, 2014
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Chan-Woong PARK, Myeong Hoon YEOM, Nam Hoon CHO, Sang Jun LEE, Sang Min LEE, Jin Young LEE, Hee Yong JEON, Young-Myeong KIM, Chun-Ki KIM, Young Deuk CHOI
  • Publication number: 20140248380
    Abstract: The present disclosure discloses a method for treating vascular inflammation, improving skin beauty and improving male sexual function of a subject by administering a ginseng berry extract to the subject.
    Type: Application
    Filed: May 9, 2014
    Publication date: September 4, 2014
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Chan-Woong PARK, Myeong Hoon YEOM, Nam Hoon CHO, Sang Jun LEE, Sang Min LEE, Jin Young LEE, Hee Yong JEON, Young-Myeong KIM, Chun-Ki KIM, Young Deuk CHOI
  • Patent number: 8652542
    Abstract: A composition according to the present invention is a composition containing extract of Panax ginseng C.A. Meyer fruit as an active ingredient for preventing or treating artherosclerosis. The extract is confirmed to effectively suppress lesions or generation of a vascular inflammation factor caused by artherosclerosis. Thus, the composition is suitable for use as an active ingredient of the composition for preventing or treating artherosclerosis.
    Type: Grant
    Filed: November 26, 2009
    Date of Patent: February 18, 2014
    Assignee: Amorepacific Corporation
    Inventors: Chan-Woong Park, Dae Bang Seo, Hee Young Jeon, Sang Min Lee, Wan Gi Kim, Sang Jun Lee, Young-Myeong Kim, Chun-Ki Kim
  • Publication number: 20120328545
    Abstract: The present disclosure discloses a method for treating vascular inflammation, improving skin beauty and improving male sexual function of a subject by administering a ginseng berry extract to the subject.
    Type: Application
    Filed: August 2, 2012
    Publication date: December 27, 2012
    Applicant: Amorepacific Corporation
    Inventors: Chan-Woong PARK, Myeong Hoon YEOM, Nam Hoon CHO, Sang Jun LEE, Sang Min LEE, Jin Young LEE, Hee Yong JEON, Young-Myeong KIM, Chun-Ki KIM, Young Deuk CHOI
  • Patent number: 8067387
    Abstract: The present invention relates to a method for stimulating angiogenesis using by DKK2 and composition comprising the same. The DKK2 protein of the present invention showed stimulating activities of tube formation on HUVEC, promoting activity of the sprouting of arterial circle tissues and promoting activity of vascular development in the embryo of mouse. Therefore, it can be used as the therapeutics or functional health food for treating and preventing ischemic disease.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: November 29, 2011
    Assignee: Theragen Etex Co., Ltd
    Inventors: Young-Guen Kwon, Jeong-Ki Min, Chae-Ok Yun, Young-Myeong Kim
  • Publication number: 20110268824
    Abstract: A composition according to the present invention is a composition containing extract of Panax ginseng C.A. Meyer fruit as an active ingredient for preventing or treating artherosclerosis. The extract is confirmed to effectively suppress lesions or generation of a vascular inflammation factor caused by artherosclerosis. Thus, the composition is suitable for use as an active ingredient of the composition for preventing or treating artherosclerosis.
    Type: Application
    Filed: November 26, 2009
    Publication date: November 3, 2011
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Chan-Woong Park, Dae Bang Seo, Hee Young Jeon, Sang Min Lee, Wan Gi Kim, Sang Jun Lee, Young-Myeong Kim, Chun-ki Kim
  • Publication number: 20100297270
    Abstract: A composition containing ginseng berry extract as active ingredient is for facilitation of blood circulation, for prevention of vascular aging, for treatment of vascular inflammation, for facilitation of angiogenesis, for treatment of ischemic heart disease, for improvement and treatment of local blood circulation insufficiency, for improvement of skin beauty and for improvement of male sexual function.
    Type: Application
    Filed: May 28, 2008
    Publication date: November 25, 2010
    Applicant: Amorepacific Corporation
    Inventors: Chan-Woong Park, Myeong Hoon Yeom, Nam Hoon Cho, Sang Jun Lee, Sang Min Lee, Jin Young Lee, Hee Yong Jeon, Young-Myeong Kim, Chun-Ki kim, Young Deuk Choi
  • Publication number: 20090275509
    Abstract: The present invention relates to a method for stimulating angiogenesis using by DKK2 and composition comprising the same. The DKK2 protein of the present invention showed stimulating activities of tube formation on HUVEC, promoting activity of the sprouting of arterial circle tissues and promoting activity of vascular development in the embryo of mouse. Therefore, it can be used as the therapeutics or functional health food for treating and preventing ischemic disease.
    Type: Application
    Filed: May 23, 2007
    Publication date: November 5, 2009
    Inventors: Young-Guen Kwon, Jeong-ki Min, Chae-Ok Yun, Young-Myeong Kim
  • Patent number: 6747050
    Abstract: The present invention provides to an isoxazoline derivative of formula (I), the pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof, and the use of the derivative in inhibiting the activity of caspases. The present invention also provides a pharmaceutical composition for preventing inflammation and apoptosis which comprise the isoxazoline derivative, pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof and the process for preparing the same. The derivative according to the present invention can be effectively used in treating diseases due to caspases, such as, for example the disease in which cells are abnormally died, dementia, cerebral stroke, AIDS, diabetes, gastric ulcer, hepatic injury by hepatitis, sepsis, organ transplantation rejection reaction and anti-inflammation.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: June 8, 2004
    Assignee: LG Chem Investment Ltd.
    Inventors: Eunice Eun-Kyeong Kim, Mi-Jeong Park, Tae-Hee Lee, Hye-Kyung Chang, Tae-Kyo Park, Chang-Yuil Kang, Young-Myeong Kim, Kwang-Yul Moon, Young-Leem Oh, Chang-Hee Min, Hyun-Ho Chung